NEW YORK (TheStreet) -- Valeant Pharmaceuticals (VRX)  stock is up by 4.11% to $89.66 in early afternoon trading after the company responded to Democratic presidential candidate Hillary Clinton's criticism of its drug price increases.

The pharmaceutical company's stock fell on Thursday after Clinton's campaign published an article and video about Valeant's D.H.E. 45 treatment for migraines. Valeant is "one of these companies that is absolutely gouging American consumers and patients," Clinton said in the video. 

A generic version of D.H.E. 45 has been available since 2003, and the company's overall market share for the drug is less than 1%, Valeant said in a statement on Thursday.

"Whenever the sales volume of a drug declines, manufacturers must consider pricing adjustments to keep production of the drug viable," the company said. "Patients are able to choose generic versions of the drug, however, at significantly lower prices."

Separately, recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.

TheStreet Recommends

TheStreet Ratings rated this stock as a "hold" with a ratings score of C. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. We also find weaknesses including a generally disappointing performance in the stock itself, unimpressive growth in net income and generally higher debt management risk.

You can view the full analysis from the report here: VRX

Image placeholder title

VRX

data by

YCharts